Swiss AI drug trial startup gets funding from Creandum
In short
A Swiss startup that uses AI for drug trials got funding from Creandum, which also backed Spotify. The company says its model was trained on about two million human RNA readouts and could replace old testing methods and animal testing with 12-week simulations.
This matters because faster testing could change how drug development is done. The amount of funding and the next milestones were not stated.
What the reporting says
A Swiss AI drug-trial startup received funding from Creandum, a backer of Spotify. The company says its AI foundation model is trained on about two million human RNA readouts and is meant to replace traditional testing and animal testing with 12-week simulations. The reporting does not state the amount raised or other deal terms.
Why it matters
The Swiss startup’s funding from Creandum supports its plan to use an AI foundation model trained on about two million human RNA readouts for drug testing. The company says the model could replace conventional and animal testing with 12-week simulations, but the reporting does not give the funding amount or confirm results. The news is relevant to biotech and AI investors.